NCT02947165 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT02947165
Title	Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.
Recruitment	Completed
Gender	both
Phase	Phase I
Variant Requirements	No
Sponsors	Novartis Pharmaceuticals
Indications	lung non-small cell carcinoma clear cell renal cell carcinoma triple-receptor negative breast cancer pancreatic cancer hepatocellular carcinoma prostate cancer Advanced Solid Tumor colorectal cancer
Therapies	NIS793 + Spartalizumab NIS793
Age Groups:
Covered Countries	USA \| ITA \| DEU \| CHE \| CAN \| AUT

NCT02947165
Clinical Trial Detail